AbbVie (ABBV) Return on Equity (2013 - 2026)

AbbVie (ABBV) has 14 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, down 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (down 2.0% YoY), and the FY2025 annual result was 0.9%, up 89.0% from the prior year.
• Return on Equity rose to 0.01% in Q1 2026 per ABBV's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.06% in Q2 2025 and troughed at 0.02% in Q3 2025.
• A 5-year average of 0.01% and a median of 0.01% in 2022 frame the typical range for Return on Equity.
• On a YoY basis, Return on Equity climbed as much as 5 bps in 2025 and fell as far as 3 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then sank by 43 bps to 0.0% in 2023, then jumped by 126 bps to 0.01% in 2024, then plunged by 258 bps to 0.01% in 2025, then soared by 49 bps to 0.01% in 2026.
• Business Quant data shows ABBV's Return on Equity at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.02% in Q3 2025.